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Purpose/Objective: To demonstrate the feasibility of 
physician driven IMRT planning with a multicriteria 
optimization (MCO) treatment planning system. The long 
term objective is to involve physicians at an earlier stage of 
the treatment planning process in order to increase planning 
efficiency and allow physicians to more naturally express 
their clinical intentions. 
Materials and Methods: This treatment planning study is 
based on data of 10 prostate and 12 central nervous system 
(CNS) cases, previously treated at Massachusetts General 
Hospital with a clinically approved MCO-IMRT treatment plan, 
created by dosimetrists. MCO Pareto surfaces were 
recalculated using identical beam geometries as in the 
clinical plans. Physicians navigated to their preferred trade-
offs and created a deliverable plan (Figure 1). For each 
patient two plans, the clinically delivered and the physician 
navigated plan, are evaluated with regard to dosimetric 
differences and physician preference. Additionally the 
required navigation times for the physicians were 
documented. 
 
 
Results: Overall plans generated by dosimetrists versus 
physicians were comparative without marked differences. 
However, evaluation of individual treatment plans 
demonstrate different focuses of planning target volumes 
(PTV) and organs at risks (OAR) and between OARs, but not in 
a consistent way. While most of the evaluated quantities do 
not show significant deviations, general differences were 
found for the brainstem (p(D1)=0.029) in CNS, where the 
physician allowed higher values of D1, and for high dose 
regions of bladder (p(D1)=0.024, p(V65)=0.003) and rectum 
(p(D1)=0.005 , p(V65)=0.009), where the physician chose 
more OAR sparing in exchange for a lower PTV coverage 
(volume of 98%-isodose: p(V6527)=0.007). The full statistical 
evaluation and a blinded plan comparison survey of both 
plans are ongoing. After some introduction to the system, 
both physicians felt comfortable navigating and exploring the 
planning possibilities. A learning curve was observable 
throughout the study: physicians developed strategies and 
navigation times were reduced (prostate: from 30 to 5 
minutes, CNS: case specific variations 15-20 minutes). 
Recorded physicians statements such as: 'it is great to see the 
trade-offs' and 'isn't that interesting how much this dose is 
decreasing for a small increase in the other?' highlight that 
physicians put great value on being able to navigate their 
own plans.  
Conclusions: Physician driven planning by Pareto surface 
navigation is feasible. Generally physicians insight into the 
planning process is of great value. With respect to clinical 
decisions and planning efficiency the gain appears to be case 
and anatomical site dependent. 
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Purpose/Objective: To compare 3D-CRT and VMAT 
pancreatic radiotherapy planning, and to assess the 
feasibility of dose escalation. 
Materials and Methods: Fourteen pancreatic 4D-CT datasets 
were planned using: i) 5-7 field 3D-CRT, prescribing 54Gy in 
30 fractions, ii) double arc VMAT, prescribing 54Gy in 30 
fractions and iii) double arc VMAT, prescribing 59.4Gy in 33 
fractions. For 3D-CRT planning and VMAT planning to 54Gy, at 
least 98% of the PTV received ≥95% of the prescription dose 
(PD). For VMAT planning to 59.4Gy, areas of PTV overlap with 
the stomach and duodenum received ≥80% of the PD, and 95% 
of the non-overlapped PTV received ≥95% of the PD, as per 
the SCALOP II protocol. The Wilcoxon signed-rank test was 
used to compare dosimetric parameters. Spearman's 
correlations assessed correlations between volumes of PTV-
duodenal and PTV-stomach overlap, and dosimetric 
parameters. 
Results: It was necessary to exceed the duodenal V55Gy 
constraint (usual limit <1cc) in order to achieve coverage in 
six 3D-CRT plans. There was a strong correlation between the 
volume of PTV-duodenal overlap and duodenal V55Gy 
(Spearman's rho: 0.79, p=0.001). Where PTV-duodenal 
overlap exceeded 20cc, 3D-CRT plans could not be created 
without exceeding duodenal constraints. All duodenal 
constraints were met in all VMAT 54Gy and 59.4Gy plans.  
